The Presentation entitled "The AmCyte Experience: Perspectives on Adult Stem Cells and Encapsulation for the Treatment of Diabetes" will highlight AmCyte commitment to advancing islet cell treatments for diabetes. AmCyte will present its approach for overcoming the key hurdles facing cell therapies for diabetes, namely a limited islet supply and the need for life-long immune suppression following islet transplantation. AmCyte has recently achieved the following milestones:

Adult Stem Cell Regenerated Islet Program
• Proof of concept that regenerated insulin-producing islet-like structures from cultures are able to treat diabetic animals successfully
• Pancreas progenitor patent granted Encapsulation Program
• Maintaining insulin-producing islets in culture for three years
• Granted one-year shelf life by Canadian FDA for encapsulated islets to be transplanted in AmCyte’s clinical trial
• Transplanting encapsulated islets into the first North American patient with diabetes without chronic immune suppression "Three month preliminary data are giving strong indication that we will achieve our primary six month safety endpoint for this study", said Dr. Gary Levy, Principle Investigator and Director of the Toronto Multi Organ Transplant Program. "We are pleased that after low dose Rapamune was withdrawn 30 days post-transplant, the patient feels well, is in good health, and shows no adverse reactions to the islets. We will continue our observations and anticipate further progress for the next two patients in this trial."

"Although the data is only preliminary, we see this clinical trial as a major step towards making islet cell treatments for patients suffering from diabetes a reality", said Dr. Wen Tsang, Sr. Vice
President R&D. "AmCyte plans to take further steps and put regenerated islets into patients in the clinic within the next two years."

Addressing strategic corporate goals for the coming two years, AmCyte CEO Terrence Soon Shiong said," We are pushing our programs toward the clinic and will be looking to raise sufficient funding to sustain our current momentum. We are looking for visionary investors who
understand the potential that a treatment for diabetes represents.

Here at AmCyte we are all proud to be working on technologies to better patient’s lives and make a positive contribution to a society trying to grapple with the human and healthcare costs of this terrible disease."

AmCyte Inc., located in Santa Monica California, specializes in islet transplantation therapy. AmCyte has developed encapsulation technology to allow transplantation of insulin-producing islets without chronic immune suppression. The company is also developing human adult stem cell approaches in its Adult Stem Cell Regenerated Islet Program to address the limited supply of transplantable islets.

Source